Brawn Biotech Ltd
Incorporated in 1985, Brawn Biotech Ltd is in the business of trading pharmaceutical products[1]
- Market Cap ₹ 6.60 Cr.
- Current Price ₹ 22.0
- High / Low ₹ 26.0 / 15.5
- Stock P/E 34.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
0.48 | |
0.49 | |
Operating Profit | -0.01 |
OPM % | -2.08% |
0.24 | |
Interest | 0.00 |
Depreciation | 0.01 |
Profit before tax | 0.22 |
Tax % | 18.18% |
0.19 | |
EPS in Rs | 0.63 |
Dividend Payout % | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | -5% |
5 Years: | -2% |
3 Years: | 5% |
1 Year: | 6% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
Equity Capital | |
Reserves | |
Total Liabilities | |
CWIP | |
Investments | |
Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
Debtor Days | |
Inventory Days | |
Days Payable | |
Cash Conversion Cycle | |
Working Capital Days | |
ROCE % |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations')
30 Sep - Re-appointed Amit Kumar as Manager Feb 12, 2026–Feb 11, 2031; shareholders adopted new MoA per Companies Act 2013.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep - 40th AGM on 30 Sep 2025: four resolutions passed, including audited FY2025 and KMP reappointments.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 30 Sep
- Proceedings Of 40Th Annual General Meeting. 30 Sep
- Closure of Trading Window 29 Sep
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BBL is a fully integrated healthcare company that deals in pharmaceutical products, covering segments:
a) Antibacterial
b) Cardiovascular
c) Antidiabetics
d) Analgesics
e) Gastrointestinal
f) Antifungals
g) Skin Care
h) Antipsychotics,
i) Anti-asthmatics
j) Antacids
k) Antimalarial
l) Nutritional